Table 2 Demographic and clinical characteristics of responders and non-responders to IFX induction treatment
Characteristics | Responders (n = 24) | Non-responders (n = 7) | p value |
|---|---|---|---|
Sex (men/women), n (%) | 16 (66.7)/8 (33.3) | 3 (42.9)/4 (57.1) | 0.26 |
Age (years) | 41.8 ± 17.1 | 48.0 ± 17.8 | 0.43 |
Disease duration (years)* | 6.5 ± 4.1 | 9.6 ± 9.2 | 0.23 |
Modified Truelove and Witts severity index* | 9.7 ± 3.2 | 10.6 ± 3.4 | 0.57 |
Mayo score (endoscopy)* | 2.8 ± 0.4 | 2.9 ± 0.3 | 0.58 |
Extent of disease | |||
Left-side type, n (%) | 12 (50.0) | 1 (14.3) | 0.09 |
Extensive colitis, n (%) | 12 (50.0) | 6 (85.7) | |
Concomitant medications | |||
Corticoteroids, n (%) | 9 (37.5) | 1 (14.3) | 0.25 |
Azathioprine/Mercaptopurine, n (%) | 11 (45.8) | 4 (57.1) | 0.60 |
Tacrolimus, n (%) | 8 (33.3) | 4 (57.1) | 0.26 |
Cytemegalovirus, n (%) | 6 (25.0) | 4 (57.1) | 0.17 |
Serum hemoglobin level >9.8 g/dl at IFX initiation, n (%) | 16 (66.7) | 2 (28.6) | 0.07 |
Serum albumin level >35 g/L at IFX initiation, n (%) | 12 (50.0) | 1 (14.3) | 0.21 |
Serum CRP level <5 mg/L at 2 weeks after IFX initiation, n (%) | 18 (75.0) | 1 (14.3) | 0.006 |